Vasoactive intestinal peptide receptor activity and specificity during enterocyte-like differentiation and retrodifferentiation of the human colonic cancerous subclone HT29-18.
Commitment of HT29-18 cells to enterocyte-like differentiation by glucose removal is related to a decreased capacity to generate cAMP after treatment with vasoactive intestinal peptide (VIP), forskolin or sodium fluoride. In contrast, the potency of VIP (EC50 = 1.1 - 1.3 X 10(-10) M) and the pharmacological specificity of the VIP receptor (VIP greater than rh GRF 1-43 greater than PHI greater than secretin) are unchanged during differentiation and retrodifferentiation. These results indicate that disturbances in VIP receptor-post-receptor activity, involving cell surface VIP receptors, membrane and intracellular transducers of hormonal information, occur during enterocyte-like differentiation of the HT29-18 subclone.
Chastre
E
E
Emami
S
S
Rosselin
G
G
Gespach
C
C
D000262:Adenylyl Cyclases / Q000378:metabolism; D002454:Cell Differentiation; D002999:Clone Cells / Q000166:cytology; D005576:Colforsin; D003110:Colonic Neoplasms / Q000378:metabolism* / Q000648:ultrastructure; D000242:Cyclic AMP / Q000096:biosynthesis; D004224:Diterpenes / Q000494:pharmacology; D006801:Humans; D007413:Intestinal Mucosa / Q000378:metabolism; D007422:Intestines / Q000166:cytology*; D011956:Receptors, Cell Surface / Q000187:drug effects / Q000378:metabolism*; D018005:Receptors, Vasoactive Intestinal Peptide; D012969:Sodium Fluoride / Q000494:pharmacology; D014660:Vasoactive Intestinal Peptide / Q000031:analogs & derivatives / Q000494:pharmacology
D004224:Diterpenes; D011956:Receptors, Cell Surface; D018005:Receptors, Vasoactive Intestinal Peptide; D005576:Colforsin; D014660:Vasoactive Intestinal Peptide; D012969:Sodium Fluoride; D000242:Cyclic AMP; D000262:Adenylyl Cyclases